beta-Lactamase Inhibitors
"beta-Lactamase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
| Descriptor ID |
D065093
|
| MeSH Number(s) |
D27.505.519.389.400 D27.505.954.122.085.516
|
| Concept/Terms |
beta-Lactamase Inhibitors- beta-Lactamase Inhibitors
- Inhibitors, beta-Lactamase
- beta Lactamase Inhibitors
- Inhibitors, beta Lactamase
- Lactamase Inhibitors, beta
- beta Lactamase Antagonists
- Antagonists, beta Lactamase
- Lactamase Antagonists, beta
|
Below are MeSH descriptors whose meaning is more general than "beta-Lactamase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "beta-Lactamase Inhibitors".
This graph shows the total number of publications written about "beta-Lactamase Inhibitors" by people in this website by year, and whether "beta-Lactamase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 14 | 7 | 21 |
| 2018 | 9 | 7 | 16 |
| 2019 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "beta-Lactamase Inhibitors" by people in Profiles.
-
Emergence of Resistance to Novel Cephalosporin-ß-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump. Antimicrob Agents Chemother. 2021 07 16; 65(8):e0008921.
-
The urgent need for metallo-ß-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2022 01; 22(1):e28-e34.
-
High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial. JAMA Netw Open. 2021 03 01; 4(3):e212713.
-
New guidelines to treat bacterial infections. Lancet Infect Dis. 2020 11; 20(11):1239.
-
What is the impact of the change in DDD of amoxicillin and amoxicillin combined with ß-lactamase inhibitors on nationwide surveillance of antimicrobial use? J Antimicrob Chemother. 2019 10 01; 74(10):3119-3121.
-
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019 08 01; 74(8):2464-2466.
-
New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs. 2019 May; 79(7):705-714.
-
Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clin Microbiol Infect. 2019 Aug; 25(8):932-942.
-
New antimicrobial options for the management of complicated intra-abdominal infections. Eur J Clin Microbiol Infect Dis. 2019 May; 38(5):819-827.
-
In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. Int J Antimicrob Agents. 2019 Aug; 54(2):261-264.